ArticleProceedings of the National Academy of Sciences of the United States of America2017
High-throughput screening of rare metabolically active tumor cells in pleural effusion and peripheral blood of lung cancer patients.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 76 citations in OpenAlex.
- Personalized chemotherapy guided by drug sensitivity of circulating tumor cells improves outcomes in advanced biliary tract cancer.Cancer cell international · 2026Article
- Single-Cell Sequencing-Guided Annotation of Rare Tumor Cells for Deep Learning-Based Cytopathologic Diagnosis of Early Lung Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Microfluidic design in single-cell sequencing and application to cancer precision medicine.Cell reports methods · 2023Review
- Single-cell metabolic fingerprints discover a cluster of circulating tumor cells with distinct metastatic potential.Nature communications · 2023Article
- Malignant pleural effusion diagnosis and therapy.Open life sciences · 2023Review
- Metabolism-Related Gene Expression in Circulating Tumor Cells from Patients with Early Stage Non-Small Cell Lung Cancer.Cancers · 2022Article
- Review
- Manipulation of single cells via a Stereo Acoustic Streaming Tunnel (SteAST).Microsystems & nanoengineering · 2022Article
- Heparin impairs skeletal muscle glucose uptake by inhibiting insulin binding to insulin receptor.Endocrinology, diabetes & metabolism · 2021Article
- Diving into the Pleural Fluid: Liquid Biopsy for Metastatic Malignant Pleural Effusions.Cancers · 2021Review
- Selective treatment pressure in colon cancer drives the molecular profile of resistant circulating tumor cell clones.Molecular cancer · 2021Article
- Methods and platforms for analysis of nucleic acids from single-cell based on microfluidics.Microfluidics and nanofluidics · 2021Review
- Deep Profiling of Cellular Heterogeneity by Emerging Single-Cell Proteomic Technologies.Proteomics · 2020Review
- Article
- Nondestructive Identification of Rare Trophoblastic Cells by Endoplasmic Reticulum Staining for Noninvasive Prenatal Testing of Monogenic Diseases.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2020Article
- L-Glucose: Another Path to Cancer Cells.Cancers · 2020Review
- Dissection of major cancer gene variants in subsets of circulating tumor cells in advanced breast cancer.Scientific reports · 2019Article
- Liquid biopsy-based single-cell metabolic phenotyping of lung cancer patients for informative diagnostics.Nature communications · 2019Article
- Sensitive molecular testing methods can demonstrate NSCLC driver mutations in malignant pleural effusion despite non-malignant cytology.Translational lung cancer research · 2019Article
- A Chemical Approach for Profiling Intracellular AKT Signaling Dynamics from Single Cells.Journal of the American Chemical Society · 2018Article
Corrections and comments
- Erratum issued
Authors and funding
10 authors at 5 institutions in 2 countries.
Funding
Abstract
Malignant pleural effusion (MPE), the presence of malignant cells in pleural fluid, is often the first sign of many cancers and occurs in patients with metastatic malignancies. Accurate detection of tumor cells in pleural fluid is crucial because the presence of MPE denotes an advanced stage of disease and directs a switch in clinical managements. Cytology, as a traditional diagnostic tool, has limited sensitivity especially when tumor cells are not abundant, and may be confounded by reactive mesothelial cells in the pleural fluid. We describe a highly sensitive approach for rapid detection of metabolically active tumor cells in MPE via exploiting the altered glucose metabolism of tumor cells relative to benign cells. Metabolically active tumor cells with high glucose uptake, as evaluated by a fluorescent glucose analog (2-NBDG), are identified by high-throughput fluorescence screening within a chip containing 200,000 addressable microwells and collected for malignancy confirmation via single-cell sequencing. We demonstrate the utility of this approach through analyzing MPE from a cohort of lung cancer patients. Most candidate tumor cells identified are confirmed to harbor the same driver oncogenes as their primary lesions. In some patients, emergence of secondary mutations that mediate acquired resistance to ongoing targeted therapies is also detected before resistance is manifested in the clinical imaging. The detection scheme can be extended to analyze peripheral blood samples. Our approach may serve as a valuable complement to cytology in MPE diagnosis, helping identify the driver oncogenes and resistance-leading mutations for targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.